An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Eli Lilly, Novo Nordisk Stocks Rise After One Just Hit a Landmark Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.
The U.S. Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the ...
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback